PL354034A1 - Polimorfizm ludzkiego genu MDR-1 i jego użycie w dPolimorfizm ludzkiego genu MDR-1 i jego użycie w diagnostyce i zastosowanich terapeutycznychiagnostyce i zastosowanich terapeutycznych - Google Patents
Polimorfizm ludzkiego genu MDR-1 i jego użycie w dPolimorfizm ludzkiego genu MDR-1 i jego użycie w diagnostyce i zastosowanich terapeutycznychiagnostyce i zastosowanich terapeutycznychInfo
- Publication number
- PL354034A1 PL354034A1 PL00354034A PL35403400A PL354034A1 PL 354034 A1 PL354034 A1 PL 354034A1 PL 00354034 A PL00354034 A PL 00354034A PL 35403400 A PL35403400 A PL 35403400A PL 354034 A1 PL354034 A1 PL 354034A1
- Authority
- PL
- Poland
- Prior art keywords
- mdr
- vectors
- proteins
- polynucleotides
- gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99114938 | 1999-07-30 | ||
| EP00103361 | 2000-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL354034A1 true PL354034A1 (pl) | 2003-12-15 |
Family
ID=26070560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL00354034A PL354034A1 (pl) | 1999-07-30 | 2000-07-28 | Polimorfizm ludzkiego genu MDR-1 i jego użycie w dPolimorfizm ludzkiego genu MDR-1 i jego użycie w diagnostyce i zastosowanich terapeutycznychiagnostyce i zastosowanich terapeutycznych |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050227249A1 (pl) |
| EP (1) | EP1232260B1 (pl) |
| JP (2) | JP2003510021A (pl) |
| KR (1) | KR100814188B1 (pl) |
| AT (1) | ATE373710T1 (pl) |
| AU (1) | AU1131901A (pl) |
| BG (1) | BG65988B1 (pl) |
| CA (2) | CA2376666C (pl) |
| CZ (1) | CZ2002329A3 (pl) |
| DE (1) | DE60036487T2 (pl) |
| DK (1) | DK1232260T3 (pl) |
| EE (1) | EE200200049A (pl) |
| ES (1) | ES2292481T3 (pl) |
| HR (1) | HRP20020093B1 (pl) |
| HU (1) | HUP0201997A3 (pl) |
| MX (1) | MXPA02001094A (pl) |
| NO (2) | NO330680B1 (pl) |
| PL (1) | PL354034A1 (pl) |
| SK (1) | SK1502002A3 (pl) |
| WO (1) | WO2001009183A2 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040191785A1 (en) * | 2000-11-29 | 2004-09-30 | Ulrich Brinkmann | Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism |
| WO2002043730A1 (en) * | 2000-11-29 | 2002-06-06 | Epidauros Biotechnologie Ag | Use of mdr-1 inducers for treating or preventing diseases |
| ATE449184T1 (de) | 2001-01-12 | 2009-12-15 | Univ Washington | Mdr1-varianten und verfahren zu ihrer verwendung |
| WO2003025174A2 (en) * | 2001-09-06 | 2003-03-27 | Bayer Healthcare Ag | Regulation of human mrp1-like protein |
| EP1340818A1 (en) | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| AU2003280867A1 (en) * | 2002-11-04 | 2004-06-07 | Charite-Universitatsme Dizin Berlin | Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy |
| PL1756310T3 (pl) * | 2004-05-12 | 2013-05-31 | Max Planck Gesellschaft | Sposób wykrywania polimorfizmów w genie ABCB1 związanych z brakiem odpowiedzi na lek działający na OUN oraz lek zawierający inhibitor ABCB1 do stosowania w leczeniu chorób związanych z OUN |
| CN101194025A (zh) * | 2005-06-13 | 2008-06-04 | 弗·哈夫曼-拉罗切有限公司 | 与急性排异反应有关的impdh2 snp |
| EP1896614A1 (en) * | 2005-06-13 | 2008-03-12 | F. Hoffmann-La Roche Ag | MDRl SNP IN ACUTE RETECTION |
| WO2006133840A1 (en) * | 2005-06-13 | 2006-12-21 | F.Hoffmann-La Roche Ag | Il10 snp associated with acute rejection |
| WO2007058896A2 (en) * | 2005-11-10 | 2007-05-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment |
| ES2394529T3 (es) | 2007-06-12 | 2013-02-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Nuevos polimorfismos en ABCB1 asociados con una falta de respuesta clínica a medicamentos |
| KR101033840B1 (ko) * | 2011-03-08 | 2011-05-16 | (주)제일엔지니어링건축사사무소 | 공동주택용 입상관 연결구조 |
| US20180365372A1 (en) * | 2017-06-19 | 2018-12-20 | Jungla Inc. | Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5206352A (en) * | 1986-03-28 | 1993-04-27 | Board Of Trustees Of The University Of Illinois | Compositions for clones containing DNA sequences associated with multidrug resistance in human cells |
| US5928637A (en) * | 1987-06-16 | 1999-07-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of inducing multidrug resistance using human MDR1 cDNA |
| US5851819A (en) * | 1987-06-16 | 1998-12-22 | National Institutes Of Health | Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells |
| JPH02100680A (ja) * | 1988-10-05 | 1990-04-12 | Suntory Ltd | ヒト正常細胞由来ｍｄｒ関連遺伝子 |
| US5399483A (en) * | 1989-03-30 | 1995-03-21 | Suntory Limited | Expression of MDR-related gene in yeast cell |
| US5856104A (en) * | 1996-10-28 | 1999-01-05 | Affymetrix, Inc. | Polymorphisms in the glucose-6 phosphate dehydrogenase locus |
| US5830697A (en) * | 1997-01-21 | 1998-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | P-glycoprotein mutant resistant to cyclosporin modulation |
-
2000
- 2000-07-28 AT AT00972654T patent/ATE373710T1/de active
- 2000-07-28 DK DK00972654T patent/DK1232260T3/da active
- 2000-07-28 CA CA2376666A patent/CA2376666C/en not_active Expired - Lifetime
- 2000-07-28 HU HU0201997A patent/HUP0201997A3/hu unknown
- 2000-07-28 CA CA2697207A patent/CA2697207A1/en not_active Abandoned
- 2000-07-28 ES ES00972654T patent/ES2292481T3/es not_active Expired - Lifetime
- 2000-07-28 EP EP00972654A patent/EP1232260B1/en not_active Expired - Lifetime
- 2000-07-28 SK SK150-2002A patent/SK1502002A3/sk unknown
- 2000-07-28 DE DE60036487T patent/DE60036487T2/de not_active Expired - Lifetime
- 2000-07-28 MX MXPA02001094A patent/MXPA02001094A/es active IP Right Grant
- 2000-07-28 AU AU11319/01A patent/AU1131901A/en not_active Abandoned
- 2000-07-28 PL PL00354034A patent/PL354034A1/pl unknown
- 2000-07-28 CZ CZ2002329A patent/CZ2002329A3/cs unknown
- 2000-07-28 KR KR1020027001248A patent/KR100814188B1/ko not_active IP Right Cessation
- 2000-07-28 EE EEP200200049A patent/EE200200049A/xx unknown
- 2000-07-28 JP JP2001513989A patent/JP2003510021A/ja active Pending
- 2000-07-28 WO PCT/EP2000/007314 patent/WO2001009183A2/en active IP Right Grant
-
2002
- 2002-01-29 NO NO20020470A patent/NO330680B1/no not_active IP Right Cessation
- 2002-01-29 BG BG106362A patent/BG65988B1/bg unknown
- 2002-01-30 HR HR20020093A patent/HRP20020093B1/xx not_active IP Right Cessation
-
2004
- 2004-10-14 US US10/965,348 patent/US20050227249A1/en not_active Abandoned
-
2010
- 2010-06-02 NO NO20100798A patent/NO20100798L/no unknown
-
2011
- 2011-01-24 JP JP2011011834A patent/JP2011142909A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20020093A2 (en) | 2004-06-30 |
| DE60036487T2 (de) | 2008-06-19 |
| JP2011142909A (ja) | 2011-07-28 |
| WO2001009183A3 (en) | 2002-03-28 |
| CA2697207A1 (en) | 2001-02-08 |
| HRP20020093B1 (en) | 2011-02-28 |
| CA2376666C (en) | 2010-05-25 |
| KR20020059347A (ko) | 2002-07-12 |
| HUP0201997A2 (en) | 2002-09-28 |
| US20050227249A1 (en) | 2005-10-13 |
| MXPA02001094A (es) | 2003-07-21 |
| NO20020470L (no) | 2002-03-26 |
| JP2003510021A (ja) | 2003-03-18 |
| KR100814188B1 (ko) | 2008-03-17 |
| BG106362A (bg) | 2002-09-30 |
| DE60036487D1 (de) | 2007-10-31 |
| ATE373710T1 (de) | 2007-10-15 |
| NO20020470D0 (no) | 2002-01-29 |
| HUP0201997A3 (en) | 2005-01-28 |
| NO20100798L (no) | 2002-03-26 |
| BG65988B1 (bg) | 2010-08-31 |
| ES2292481T3 (es) | 2008-03-16 |
| EP1232260A2 (en) | 2002-08-21 |
| SK1502002A3 (en) | 2002-07-02 |
| EE200200049A (et) | 2003-04-15 |
| DK1232260T3 (da) | 2008-02-04 |
| CZ2002329A3 (cs) | 2002-07-17 |
| CA2376666A1 (en) | 2001-02-08 |
| EP1232260B1 (en) | 2007-09-19 |
| AU1131901A (en) | 2001-02-19 |
| WO2001009183A2 (en) | 2001-02-08 |
| NO330680B1 (no) | 2011-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020093A2 (en) | Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications | |
| BRPI0510206A (pt) | método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação | |
| WO2004053079A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins | |
| NZ531570A (en) | DNA sequences for human angiogenesis genes | |
| WO2005080581A3 (en) | Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression | |
| WO2001020026A3 (en) | POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | |
| Chang et al. | rAAV-CRISPRa therapy corrects Rai1 haploinsufficiency and rescues selective disease features in Smith-Magenis syndrome mice | |
| WO2000077239A3 (en) | Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses | |
| Pang et al. | High-throughput sequencing offers new insights into 5-hydroxymethylcytosine | |
| WO2004050860A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| EP1223217A4 (en) | TRANSPORTER GENES OATP-B, C, D AND E | |
| WO2004053075A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| AU3925701A (en) | Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications | |
| WO2004013311A3 (en) | Compositions and methods relating to ovarian specific genes and proteins | |
| WO2003106648A3 (en) | COMPOSITIONS AND METHODS RELATED TO BREAST SPECIFIC GENES AND PROTEINS | |
| WO2004050858A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| Benson et al. | Development of Targeted Therapies Based on Gene Modification | |
| DE50312502D1 (de) | Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen | |
| WO2004052290A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| Holcomb et al. | GRHD PLANNING COMMITTEE | |
| Bauersachs et al. | Novel human neurodevelopmental and neurodegenerative disease associated with IRF2BPL gene variants—mechanisms and therapeutic avenues | |
| WO2003020953A3 (en) | Compositions and methods relating to colon specific genes and proteins | |
| WO2004053077A3 (en) | Compositions,splice variants and methods relating to breast specific genes and proteins | |
| NAFEA et al. | Study of Vascular Endothelial Growth Factor Gene Polymorphism in Acute Myeloid Leukemia Patients | |
| WO2003060121A3 (en) | Compositions and methods relating to gastric specific genes and proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |